Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 15/20 | 0.50 |
| ▸ | MMP9 | P14780 | 14/20 | 0.50 |
| ▸ | MMP8 | P22894 | 12/20 | 0.50 |
| ▸ | MMP1 | P03956 | 9/20 | 0.48 |
| ▸ | FCER2 | P06734 | 3/20 | 0.48 |
| ▸ | MMP3 | P08254 | 6/20 | 0.42 |
| ▸ | MMP7 | P09237 | 5/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | MMP12 | P39900 | 2/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552717 | 0.92 | MMP1 (0.52) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL5558426 | 0.92 | MMP1 (0.52) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL5557500 | 0.89 | MMP2 (0.47) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL5552331 | 0.89 | MMP2 (0.47) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL6245527 | 0.89 | MMP2 (0.47) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL5558591 | 0.87 | MMP2 (0.43) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL5552631 | 0.82 | MMP2 (0.42) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL5556745 | 0.82 | MMP2 (0.42) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL5552411 | 0.80 | MMP1 (0.42) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL5558074 | 0.79 | MMP2 (0.38) | MMP2MMP9MMP8MMP1FCER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | MMP2 85/4885MMP9 182/4885MMP8 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.